Drug intelligence / Profile preview

COYA 202

Development stage: Unknown
Lead developer: Coya Therapeutics
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cell Therapies

Overview

COYA 202 is an allogeneic Treg-derived exosome-based therapy developed by Coya Therapeutics. It is currently undergoing Phase 1 clinical studies for the treatment of frontotemporal dementia (FTD).

Beyond the preview

Go deeper on COYA 202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COYA 202.

Explore the full profile